ArticlemAbs2025
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L.
Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics.Oncoimmunology · 2026Review
- Review
- Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies.Biomolecules · 2026Review
- Host cell protein impurities in therapeutic proteins: overview of advances in detection, nonconventional removal technologies and immunogenicity assessment.Journal of biological engineering · 2026Review
- Construction of an Immunosensor Based on the Affinity DNA Functional Ligands to the Fc Segment of IgG Antibody.Biosensors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multispecific antibodies (msAbs) are becoming more prevalent as formats of choice for therapeutic antibody development due to their ability to modulate multiple biological targets. However, msAbs present unique protein production challenges due to product-related impurities, which are difficult to remove without loss of the protein of interest. Here, we report a versatile approach to remove product-related impurities by altering the binding affinity of light chains to Kappa Select (KS) or Protein L (Pro-L) resins. Introduction of amino acid mutations in the constant light chain domain or Framework 1 of the light chain abolished binding to KS and Pro-L resins, respectively, while antigen binding affinity remained intact. These purification-enabling mutations (PEMs) did not affect the thermal stability or purity of the proteins tested. In conjunction with PEMs, we demonstrate the design and application of an entirely affinity-based purification scheme employing Protein A (Pro-A), followed by KS and Pro-L affinity resins, to remove light chain mispaired species in Y-shaped bispecific antibodies and crossover dual variable domain (CODV) tri-specific antibodies. In principle, this purification scheme could be applied to any IgG-like msAb since it is compatible with Fc knobs-into-holes mutations and Fab arm charge-pair mutations. Moreover, it should be adaptable across a range of production scales and medium to high-throughput purification workflows within early-stage research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.